Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.33 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578376 | 0.72 | PDPK1 (0.52) | PDPK1ADRB2LOXL2CYP2A6HSP90AA1 | |
| SCHEMBL102331 | 0.71 | PDPK1 (0.59) | PDPK1ADRB2LOXL2CYP2A6HSP90AA1 | |
| SCHEMBL3661051 | 0.70 | CYP2A6 (0.31) | CYP2A6PDK1 | |
| SCHEMBL28358060 | 0.69 | PDPK1 (0.40) | PDPK1ADRB2LOXL2CYP2A6HSP90AA1 | |
| SCHEMBL5075003 | 0.69 | PDPK1 (0.39) | PDPK1ADRB2LOXL2CYP2A6HSP90AA1 | |
| SCHEMBL28007978 | 0.69 | SYK (0.40) | PDPK1ADRB2LOXL2CYP2A6HSP90AA1 | |
| SCHEMBL30632310 | 0.69 | PDPK1 (0.56) | PDPK1ADRB2LOXL2CYP2A6HSP90AA1 | |
| SCHEMBL31556353 | 0.69 | PDPK1 (0.56) | PDPK1ADRB2LOXL2CYP2A6HSP90AA1 | |
| SCHEMBL30534095 | 0.69 | PDPK1 (0.56) | PDPK1ADRB2LOXL2CYP2A6HSP90AA1 | |
| SCHEMBL28154527 | 0.69 | PDPK1 (0.56) | PDPK1ADRB2LOXL2CYP2A6HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016128356-A1 | LIGHT-ABSORBING COMPOUNDS | Technische Universität Dresden (DE) | 2016-08-18 | — | — | WO | claimed |
| CN-105209031-A | Novel antiviral agents against HBV infection | UNIV DREXEL | 2015-12-30 | — | — | CN | claimed |
| EP-2443124-A1 | SUBSTITUTED -1,3,8-TRIAZASPIRO[4.5]DECANE-2,4-DIONES | Merck Sharp & Dohme Corp. (US) | 2012-04-25 | — | — | EP | claimed |
| WO-2010147776-A1 | SUBSTITUTED -1,3,8-TRIAZASPIRO[4.5]DECANE-2,4-DIONES | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | WO | claimed |
| EP-1730148-A4 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | ABBOTT LAB (US) | 2009-08-19 | — | — | EP | claimed |
| WO-2008016643-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | claimed |
| EP-1730148-A2 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | Abbott Laboratories (US) | 2006-12-13 | — | — | EP | claimed |
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABBOTT LABORATORIES | 2006-02-02 | — | — | US | claimed |
| WO-2005074603-A2 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2005-08-18 | — | — | WO | claimed |
| WO-2005010534-A1 | EP1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF BENIGN PROSTATIC HYPERTROPHY AND SCREENING METHOD | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | claimed |
| US-20050020646-A1 | Treatment of BPH | PFIZER INC. | 2005-01-27 | — | — | US | claimed |
| EP-0992492-B1 | Small molecule inhibitors of rotamase enzyme activity | GUILFORD PHARM INC (US) | 2004-08-25 | — | — | EP | claimed |
| US-6376503-B1 | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC | 2002-04-23 | — | — | US | claimed |
| EP-1023068-A4 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2001-05-16 | — | — | EP | claimed |
| EP-1023068-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2000-08-02 | — | — | EP | claimed |
| EP-0992492-A1 | Small molecule inhibitors of rotamase enzyme activity | GUILFORD PHARMACEUTICALS INC. (US) | 2000-04-12 | — | — | EP | claimed |
| EP-0685479-B1 | Heterocyclylcarbonyl substituted benzofuranyl- and -thiophenyl-alkanecarboxyclic acid derivatives | BAYER AG (DE) | 1999-01-13 | — | — | EP | claimed |
| WO-1998057638-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1998-12-23 | — | — | WO | claimed |
| EP-0685479-A1 | Heterocyclylcarbonyl substituted benzofuranyl- and -thiophenyl-alkanecarboxyclic acid derivatives | BAYER AG (DE) | 1995-12-06 | — | — | EP | claimed |
| EP-0150939-A1 | Dihydropyridine anti-ischaemic and antihypertensive agents | Pfizer Limited (GB) | 1985-08-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABL1, MAP3K19, MAP3K20 | PDPK1 253/4885ADRB2 2581/4885LOXL2 1671/4885 |
| US-20050020646-A1 | Treatment of BPH | BPHL, PTGER1, PTGER2 | PDPK1 3541/4885ADRB2 88/4885LOXL2 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.